Neil Morganstein, MD
Following the encouraging overall survival (OS) data with durvalumab (Imfinzi) in patients with unresectable stage III non–small cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy, the next steps include biomarker research and moving the agent into earlier treatment settings, according to Neil Morganstein, MD.
In updated findings of the phase III PACIFIC trial, which was the basis for the FDA approval of durvalumab in this setting, the 2-year OS rate in the durvalumab group was 66.3% compared with 55.6% for placebo.
Updated analyses regarding progression-free survival (PFS) were similar to those previously reported, with a median duration of 17.2 months in the durvalumab arm and 5.6 months in the placebo group. Median time to death or distant metastasis was 28.3 months for patients treated with the PD-1 inhibitor versus 16.2 months for those who received placebo.
... to read the full story